[THE INVESTOR] South Korean biopharmaceutical firm Bioleaders has passed the final review for transferring its stocks to the country’s tech-heavy KOSDAQ from KONEX, the bourse operator Korea Exchange said on July 5. 

Bioleaders will be listed on KOSDAQ on July 7 with the indicative share price set at 15,000 won (US$12.87).

Established in 1999, the firm has a range of core technologies to develop next-generation immunity treatments. In 2015, Bioleaders logged 1.47 billion won in sales and a net loss of 18.6 trillion won.

By Park Han-na (hnpark@heraldcorp.com)